Download Free Global Technical Strategy For Malaria 2016 2030 2021 Update Book in PDF and EPUB Free Download. You can read online Global Technical Strategy For Malaria 2016 2030 2021 Update and write the review.

The World Health Organization's Global Technical Strategy for Malaria 2016- 2030 has been developed with the aim to help countries to reduce the human suffering caused by the world's deadliest mosquito-borne disease. Adopted by the World Health Assembly in May 2015 it provides comprehensive technical guidance to countries and development partners for the next 15 years emphasizing the importance of scaling up malaria responses and moving towards elimination. It also highlights the urgent need to increase investments across all interventions - including preventive measures diagnostic testing treatment and disease surveillance- as well as in harnessing innovation and expanding research. By adopting this strategy WHO Member States have endorsed the bold vision of a world free of malaria and set the ambitious new target of reducing the global malaria burden by 90% by 2030. They also agreed to strengthen health systems address emerging multi-drug and insecticide resistance and intensify national cross-border and regional efforts to scale up malaria responses to protect everyone at risk.
As WHO's technical department for malaria, the Global Malaria Programme has an important role to play in leading the global response against this disease. Through its direct actions and network, it has the potential to shape the malaria ecosystem and achieve impact at country level. With this in mind, the Global Malaria Programme has developed an operational strategy outlining its priorities for the period 2024‒2030 and the 4 strategic levers to control and eliminate malaria that are decisively within the Programme’s mandate: norms and standards, new tools and innovation, strategic information for impact, and leadership. The strategy describes how the Global Malaria Programme will also transform by collaborating more effectively with other programmes, regional and country offices and partners, guided by lessons learned from WHO’s Thirteenth General Programme of Work (GPW13) and the GPW14 priorities.
This report delivers the first systematic analysis of available data to make an authoritative statement on the status of inequality in HIV/AIDS, TB and malaria. Monitoring inequalities in HIV/AIDS, tuberculosis and malaria (in terms of burden, prevention and treatment) helps to pinpoint where there may be gaps and identify population groups that are being left behind, and support countries and international organizations to tailor policies, programmes, and service provision to close these gaps. The objectives of the report are to: assess the latest status and change of inequality in HIV/AIDS, malaria and tuberculosis globally; identify good-performing countries in terms of equity as well as countries that have room for improvement; and investigate the association of inequality with inequality in other health topics, social determinants of health and access to health facilities. This report supports Output 4.1.2 of GPW 13 (GPW 13 impacts and outcomes, global and regional health trends, Sustainable Development Goal indicators, health inequalities and disaggregated data monitored). Similar analysis have been previously conducted and published for other disease topics, including State of inequality: Childhood immunization and State of inequality: Reproductive, maternal, newborn and child health.
Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPCs published here aim to articulate the public health need, preferred characteristics, and clinical development considerations for drugs for malaria chemoprevention. WHO recommends several chemoprevention strategies for malaria control, including seasonal malaria chemoprevention, perennial malaria chemoprevention, intermittent preventive treatment of malaria in pregnancy, and mass drug administration. These strategies face a number of challenges such as suboptimal adherence and coverage and the emergence and spread of drug resistance. This document presents PPCs for the development of drugs for malaria chemoprevention in children, in pregnancy and in non-immune travellers, and outlines potential clinical development approaches, including the repurposing of approved malaria treatments for use as chemoprevention, recombining approved individual drugs into new combinations for malaria prevention, and the development of new drug combinations specifically for chemoprevention.
Relapsing malaria caused by Plasmodium vivax parasites poses a significant challenge to global malaria elimination efforts. About one third of the population remains at risk of contracting P. vivax malaria, and 85% of P. vivax infections stem from reactivated latent parasites, leading to chronic anaemia and increased morbidity and mortality. In addition to diagnostic tools that can detect the acute, blood-stage of P. vivax, new tools are needed to detect the dormant infections before they reactivate and contribute to morbidity and onwards transmission. To help guide research and development efforts in this area, WHO has developed two preferred product characteristics (PPCs) to detect the risk of P. vivax relapse. The first PPC is for point-of-care (POC) tests to identify individuals at risk of relapse to guide radical cure and case management. The second PPC is for laboratory-based tests to screen communities or individuals, facilitating surveillance and monitoring efforts for P. vivax control and elimination. These tools aim to improve screening, the use of radical cure and case management among high-risk populations, and support population-level risk stratification for the targeting of interventions and the monitoring and evaluation of ongoing elimination programmes.
The World health statistics report is the World Health Organization's (WHO) latest annual compilation of health and health-related indicators for its 194 Member States. The 2023 edition consolidates data for 50+ health and health related indicators (SDGs and GPW13).